These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12176401)

  • 41. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants.
    Carreño MR; Kato T; Weppler D; Mathew JM; Fuller L; Gomez C; Salman F; Garcia-Morales R; Ciancio G; Burke GW; Esquenazi V; Miller J; Tzakis AG
    Transplant Proc; 2001; 33(1-2):1015-7. PubMed ID: 11267170
    [No Abstract]   [Full Text] [Related]  

  • 43. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 44. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
    Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody.
    Garrity ER; Villanueva J; Bhorade SM; Husain AN; Vigneswaran WT
    Transplantation; 2001 Mar; 71(6):773-7. PubMed ID: 11330541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
    Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
    [No Abstract]   [Full Text] [Related]  

  • 53. IL-2 antibody induction and the outcome of pediatric renal transplants.
    Garcia CD; Barros VR; Schneider L; Alves MD; Silveira CG; Garcia VD
    Transplant Proc; 2002 Nov; 34(7):2914-5. PubMed ID: 12431655
    [No Abstract]   [Full Text] [Related]  

  • 54. Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients.
    Lo YC; Ho HC; Wu MJ; Chen CH; Cheng CH; Yu TM; Chuang YW; Huang ST; Yang CK; Shu KH
    Ren Fail; 2012; 34(7):856-61. PubMed ID: 22583338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J; Símová M; Nosková L; Teplan V; Vítko S
    Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract]   [Full Text] [Related]  

  • 56. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
    Schnitzler MA; Woodward RS; Lowell JA; Singer GG; Brennan DC
    Transplant Proc; 1999 May; 31(3B Suppl):19S-21S. PubMed ID: 10330963
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical effect of induction therapy with monoclonal antibodies after deceased-donor kidney transplantation (an experience from Vilnius Center)].
    Rainiene T; Dobrovolskiene R; Dainys B; Kucinskis G; Zelvys A
    Medicina (Kaunas); 2007; 43 Suppl 1():109-13. PubMed ID: 17551287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of basiliximab and daclizumab in kidney transplantation.
    Olyaei AJ; Thi K; deMattos AM; Bennett WM
    Prog Transplant; 2001 Mar; 11(1):33-7; quiz 38-9. PubMed ID: 11357555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
    van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO
    Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.